Jerusalem Post: Israeli oral COVID vaccine heads to Mexico, aims to fast-track approval

Oramed Pharmaceuticals, the developer of the Oravax oral COVID-19 vaccine candidate, has announced a partnership with Mexico’s Genomma Lab Internacional to help fast-track a Phase II clinical trial and gain emergency use authorization in the Latin American country. Read more here.

You may also be interested

Join our mailing list

Skip to content